Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.51 |
| ▸ | RELA | Q04206 | 5/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28572940 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL2134157 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL13334908 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL12951314 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL31454795 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL2134159 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605621 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL4951462 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL5270119 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL605148 | 0.86 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440173-B1 | STABLE LIQUID DETERGENT COMPOSITION CONTAINING SELF-STRUCTURING SURFACTANT SYSTEM | PROCTER & GAMBLE (US) | 2024-05-08 | — | — | EP | claimed |
| US-6562861-B1 | (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50 less-than 1.mu.M). Bactericides or viricides | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250302678-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | PROCTER & GAMBLE (US) | 2025-10-02 | — | — | US | disclosed |
| US-12325646-B2 | Fertigation water treatment | UNIVERSITY OF GUELPH (CA) | 2025-06-10 | — | — | US | disclosed |
| WO-2025106788-A1 | PI3Kα INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7038059-B2 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
| US-20040121482-A1 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1210324-B1 | SUBSTITUTED CYCLOPENTENES, THEIR PREPARATION AND THEIR USE FOR CHIRAL SCAFFOLDS | CHIROTECH TECHNOLOGY LTD (GB) | 2004-03-31 | — | — | EP | disclosed |
| EP-1334969-A1 | PROCESS FOR PREPARATION OF 4-N-SUBSTITUTED AMINO-2-AZA-1-OXABICYCLO 3.3.0]OCT-2-ENE-6-CARBOXYLIC ACID ESTERS AND PROCESS FOR PREPARATION OF THEIR INTERMEDIATES | KURARAY CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6593489-B1 | Catalytic stereoselective hydrogenation | CHIROTECHTECHNOLOGY LIMITED (GB) | 2003-07-15 | — | — | US | disclosed |
| US-6562861-B1 | (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50 less-than 1.mu.M). Bactericides or viricides | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | NFKB1 1350/4885NFKB2 986/4885RELA 871/4885 |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | NFKB1 916/4885NFKB2 1518/4885RELA 829/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | NFKB1 126/4885NFKB2 99/4885RELA 313/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | NFKB1 3120/4885NFKB2 2987/4885RELA 3547/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | NFKB1 2464/4885NFKB2 2073/4885RELA 1628/4885 |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | NFKB1 3836/4885NFKB2 4420/4885RELA 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.